This page shows the latest migalastat news and features for those working in and with pharma, biotech and healthcare.
Galafold (migalastat) is an oral medication for the treatment of Fabry disease, a rare lysosomal metabolic storage condition.
Galafold (migalastat) will be the first new Fabry treatment on the US market in more than 15 years, and will compete with Sanofi’s infusion-based Fabrazyme treatment.
Follows publication of Ministry of Health's reimbursement guidelines. US biotech Amicus Therapeutics has launched its new Fabry disease treatment Galafold (migalastat) in Italy after winning reimbursement coverage.
disorder. The UK's cost-effectiveness regulator has published final guidance endorsing the use of Galafold (migalastat) for Fabry, an inherited lysosomal storage disease caused by deficiency in the enzyme ... At one point migalastat was licensed to
Amicus Therapeutics' Galafold (migalastat) has also received the go-ahead, and has been sanctioned by the SMC for the treatment of adults with Fabry disease, an incurable inherited genetic disorder.
Recommends oral alternative for treating Fabry disease. The UK's NICE has recommended the use of Galafold (migalastat) on the NHS for the treatment of Fabry disease in draft Highly Specialised
More from news
Approximately 2 fully matching, plus 5 partially matching documents found.
Acquisition of remaining rights. 1034. Scioderm. Amicus. Galafold [migalastat] for Fabry's disease.
Firstly, GSK decided to return rights to the experimental Fabry disease drug migalastat, noting that support would continue through GSK's equity investment of $3m.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...